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Abstract
Thrombocytopenia is a common complication of both chronic liver disease and liver 
transplantation (LT). The mechanism of thrombocytopenia is multifactorial implicating 
not only sequestration in the spleen, or in the graft, reduction in the mean platelet survival 
but also decreased platelet production due to low synthesis of thrombopoietin (TPO) or 
direct toxicity to the bone marrow. Platelets play a dualistic role in liver transplant, both 
beneficial and detrimental. The beneficial role of platelets is due to platelet-derived sero-
tonin that is involved in liver regeneration. During surgery for liver transplant, in addi-
tion to the preoperative causes for thrombocytopenia, we have other mechanisms that 
will contribute to further deterioration of the platelets count and function: hemodilution, 
immunological reactions, and sequestration in the newly transplanted graft. This might 
result in a life-threatening level of thrombocytes. The concern is when we should treat 
thrombocytopenia because despite life-saving benefits, transfusion has also been related 
to complications and platelet transfusion has been identified as an independent risk fac-
tor for postoperative complications. Risks related to platelet concentrate administration 
are allergic reactions, alloimmunization, bacterial sepsis, and transfusion-related acute 
lung injury (TRALI). Administration of platelets is not indicated if there is no bleeding or 
immediate bleeding risk. New emerging therapies like thrombopoietin-receptor agonist 
will furthermore limit the administration of blood products.
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1. Introduction
Thrombocytopenia is a common complication of both chronic liver disease and liver trans-
plantation (LT) contributing to the complex hemostasis disturbances of those patients. Liver 
disease induces a complicated imbalance between pro- and antihemostatic elements, throm-
bocytopenia just being one of them. The mechanism of thrombocytopenia is multifactorial 
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implicating not only sequestration in the spleen, reduction in the mean platelet survival but 
also decreased platelet production due to low synthesis of thrombopoietin (TPO) [1].
In chronic liver disease, a low platelet count is a marker of severity and is associated with 
poorer prognosis [2].
Liver transplantation (LT), the main treatment of end-stage liver disease, can also induce 
decrease of thrombocytes starting intraoperative with the reperfusion syndrome and going on 
after the procedure due to several mechanisms among which sequestration in the graft plays 
an important role [1]. Platelets have a dualistic role in LT, both beneficial and detrimental [3].
Thrombocytopenia is defined by platelet count <150,000/mm3; it is mild if platelets are 
between 75,000 and 150,000/mm3, moderate for values between 50,000 and 75,000/mm3, and 
severe if the count is <50,000/mm3. Definitions may vary and the limits of platelet count might 
be different in different studies [4].
The incidence of decreased platelets in chronic liver disease is as high as 76% but moderate 
in only 13% and severe in 1% of cirrhotic patients [5]. The degree of thrombocytopenia is 
dependent on the stage of cirrhosis. However, spontaneous bleeding does not occur unless 
the values reaches 10,000–20,000/mm3. There is a difference if an invasive procedure such as 
liver biopsy, variceal ligation, paracentesis, or major surgery is intended; platelet threshold 
levels are higher and differ depending on the invasiveness of the maneuver. However, bleed-
ing is not the only concern with thrombocytopenia as platelets have other roles in inflamma-
tion, angiogenesis, antimicrobial defense and, of specific importance, in ischemia/reperfusion 
injury and a beneficial role in liver regeneration [6].
2. Causes/mechanisms for thrombocytopenia in liver transplant
2.1. Thrombocytopenia and platelet dysfunction in liver disease
Platelet count, as well as their function, is altered in patients with cirrhosis in the waiting 
list for transplantation. The pathogenesis of this phenomenon is not well understood. There 
are several mechanisms implicated in this process: on one hand, depletion of platelets due 
to destruction and on the other, an altered production. The main cause seems to be platelet 
sequestration in the enlarged, congestive spleen due to portal hypertension.
Apart from hypersplenism, other causes are reduced production of platelets, low TPO levels, 
existence of antiplatelet antibodies, alcohol toxicity, folate deficiency, chronic low-grade dis-
seminated intravascular coagulation, and direct viral suppression of platelet production as 
provided in Table 1 [7, 8].
There is a strong correlation between spleen volume and thrombocytopenia, thus measures 
that aim to diminish hypersplenism will probably have a good impact on platelet count. 
Splenectomy prior to transplantation has been proposed as a therapeutic option to increase 
platelet count but this approach remains controversial because splenic pooling is not so 
significant as it was first described and the removal of the spleen does not always lead to 
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substantial and persistent increase in thrombocytes. On the other hand, elimination of the 
spleen increases the risk of septic complications and portal thrombosis [4].
Shunt procedures done either surgically or percutaneously [transjugular intrahepatic por-
tosystemic shunt (TIPS)] are intended at decreasing portal hypertension and hypersplenism 
might also have a beneficial effect on platelet count. Massoud, following 92 patients that had 
a TIPS placement, reported a significant increase in platelet number after the procedure, this 
increase being more important in patients with more severe thrombocytopenia. But TIPS 
would not have any effect on TPO, this being a possible reason why in some cases there was 
no effect on platelet number [7].
Cirrhotic patients waiting for transplantation are sometimes in need for invasive procedures 
like liver biopsies, endoscopic variceal ligation, paracentesis, and transjugular intrahepatic 
portosystemic shunt. There is no absolute threshold of platelet count for performing any of 
those procedures but if platelets are <75,000/mm3, the risk of bleeding seems to be higher [4].
Thrombocytopenia was also a concern in patients with hepatitis C virus (HCV), who needed 
antiviral therapy with interferon and had to reduce doses or even stop treatment. Nowadays 
with the new antiviral therapies, this should not be a problem anymore.
TPO is a thrombopoietic hormone produced in the liver by both parenchymal cells and sinu-
soidal endothelial cells at a constant rate. The blood level of TPO is dependent on the uptake 
by platelets and megakaryocytes, where it is destroyed so if platelet count decreases, less 
TPO will be uptake and destroyed and its level will rise. Production of TPO is dependent on 
liver cell integrity; if that is impaired, production will decrease as in cirrhosis. This explains 
why with a reduction in platelet number TPO level in liver disease would not be elevated, as 
production is lower. TPO level is inappropriate to platelet level and as a consequence the bone 
marrow stimulation to produce thrombocytes would not be adequate [2, 4].
Antiplatelet antibodies contribute to the premature destruction of the thrombocytes. It was 
shown among patients with liver disease that up to 64% irrespective of the etiology have 
platelet-associated anti-glycoprotein (anti-GP) antibodies that are directed against the GP 
IIb-IX complex. The serum of those patients also has higher levels of platelet-associated 
immunoglobulin G also implicated in the immune-mediated destruction of platelets [2].
Mechanisms
Altered production Low TPO levels
Bone marrow suppression (HCV, alcohol)
Medication
Sequestration Congestive spleen due to portal hypertension
Enhanced destruction/loss Platelet antibodies
Chronic low-grade disseminated intravascular coagulation
Bleeding
Table 1. Causes for thrombocytopenia in chronic liver disease.
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Decreased platelet production by the bone marrow is also one of the mechanisms impli-
cated in thrombocytopenia of chronic liver disease. HCV directly inhibits the growth and 
differentiation of bone marrow stem cells and alcohol leads to ineffective megakaryopoiesis. 
Production of platelets is also inhibited by some of the medication those patients might need, 
for example, interferon [2].
Bleeding is not as frequent in cirrhotic patients as one can imagine and that can be explained 
by some compensatory mechanisms. Part of the complex problem of platelet function in cir-
rhosis is the demonstrated capacity of platelets to sustain thrombin generation at an equal 
level with control if adjusted to normal levels. This concludes that their function might not 
be as altered as primary thought [9]. And there are compensatory mechanisms to bleeding 
disorders of the cirrhotic patient, one of them being the elevated level of von Willebrand fac-
tor reaching 10-fold the plasma level of control and supporting platelet adhesion better than 
in healthy volunteers [3, 10].
2.2. Intraoperative challenges
Liver transplantation is a huge challenge with any anesthesiologist for two main problems 
such as hemodynamic changes during surgery and coagulation status of the patient. Surgery 
consists of three phases: removal of the cirrhotic liver during which, due to portal hyper-
tension, there is a high bleeding risk aggravated by the patients’ coagulopathy; the anhe-
patic phase with hemodynamic disturbances; and the neohepatic phase that starts with the 
reperfusion of the graft inducing hypotension, cardiac rhythm disturbances, and impacts on 
coagulation.
During surgery, in addition to the preoperative causes for thrombocytopenia, we have other 
mechanisms that will contribute to further deterioration of the platelets count and function 
such as bleeding, hemodilution, immunological reactions, and sequestration in the newly 
transplanted graft [3].
Several authors present the hypothesis that removal of the spleen during LT procedure will 
ameliorate platelet count. Ohira et al. [11] reported an analysis of the relationship between 
preoperative spleen volume and thrombocytopenia and suggested that splenectomy might 
be considered simultaneously with LT in chronic hepatitis C virus (HCV) patients with a 
preoperative platelet count of <60,000/mm3. The intent is to facilitate an interferon therapy 
immediately after LT. Almost all recipients will have a reinfection of the graft with HCV; they 
need antiviral therapy during the postoperative period but this might be impossible to apply 
due to thrombocytopenia. However, there are risks related to splenectomy; patients are prone 
to develop portal vein thrombosis and have a higher risk for infection and sepsis.
Morimoto et al. [12] analyzed their results for 36 patients undergoing LT and reported similar 
conclusions. Their criteria for performing splenectomy were a platelet count <50,000/mm3 and 
a spleen volume reported to the body surface area of >400 ml/m2 and so it was done in six 
patients, all of them completing their interferon therapy after LT. They registered only one 
systemic infection possibly related to splenectomy.
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In the publication by Chu et al. addressing 40 patients selected for splenectomy during LT 
because they had HCV infection associated with hypersplenism or they were expected to 
develop small-for-size syndrome or they had huge spleens that affected surgical maneuvers 
during transplant. In this selected group of patients, the authors indicated that simultaneous 
splenectomy did not increase the rate of perioperative complications or risk of mortality [13].
All the authors do not have the same opinion. In a recently published study recording 169 
patients who underwent living-related LT with splenectomy [14], the authors found that con-
comitant splenectomy with LT surgery did not increase platelet count in the early postopera-
tive period but they had more reinterventions due to hemorrhage, the operative time was 
longer, intraoperative blood loss was higher, and the incidence of lethal infectious disease was 
higher when compared to patients not having splenectomy during living donor LT.
Reperfusion of the graft is one of the most delicate moments during transplant surgery result-
ing not only in hemodynamic changes but also in alterations of the circulating platelets. 
Decreased aggregation of thrombocytes has been observed after reperfusion of the liver with 
a peak value within 1 hour and postoperative reduction in platelet surface markers glycopro-
tein (GP) IIb/IIa and P selectin [15]. Secondary to ischemia/reperfusion, platelets will suffer 
in number and function. They undergo a decrease by 30–55% due to entrapment in the graft. 
Platelets will adhere to the sinusoidal endothelium that has been activated during the cold 
and warm ischemia and will induce direct injury to the liver cell [3].
There is also a rare condition that might lead to severe thrombocytopenia after transplanta-
tion such as de novo development of idiopathic thrombocytopenic purpura [3].
2.3. Postoperative outcome
After transplantation, thrombocytopenia occurs during the first days and is a common dis-
order. The lowest values are observed on days 3–5 and if no complication happens, the reso-
lution of the process will start after the first week. The main mechanism implicated in this 
thrombocytopenia is the sequestration of the platelets in the graft (Table 2). However, the 
lowest the platelets count in this period, the most severe and complicated the course of the 
posttransplant period [16].
Mechanisms






Table 2. Causes for thrombocytopenia post liver transplant.
Thrombocytopenia in Liver Transplant
http://dx.doi.org/10.5772/intechopen.72510
89
Lesurtel et al. proposed a new criterion in evaluating the extent and impact of thrombocy-
topenia they called the 60-5 criterion. In their study, they demonstrated a strong correlation 
between a platelet count of <60,000/mm3 on postoperative day 5 and the incidence of severe 
complications and a twofold increase in mortality at 90 days [17].
A rare cause of low platelet count in this stage is heparin-induced thrombocytopenia, heparin 
therapy being the standard of care in many centers post LT. Bachmann et al. in a single center 
study looking at 205 LT found in 1.95% of patients, a suspicious clinical platelet course with 
elevated antibody levels [18].
Chang et al. looked at the role platelets have in antimicrobial host defense. They analyzed 50 
LT recipients and looked at the impact of thrombocytopenia as a related variable to infectious 
complications in the posttransplant period. They found a significant correlation between low 
platelet count (<30,000/mm3) and infections in the first month following transplantation. The 
correlation was very strong for fungal and bacterial infections but not for viral ones. Infection 
can determine thrombocytopenia but the authors stated that the lowest platelet count pre-
ceded the infection with a median time of 7 days [19].
Generally, platelet transfusion is not needed during the postoperative period and one can 
wait for the spontaneous resolution. Resolution starts after the first week due to increasing 
levels of thrombopoietin. It will reach normal values on time due to the regression of spleno-
megaly once portal hypertension has been resolved [20].
After liver transplantation, the blood level of TPO increases but it will take several days for 
the rise of platelet number to happen [21].
The beneficial role of platelets is due to platelet-derived serotonin that is involved in liver 
regeneration. This phenomenon is of great importance in living-related LT, small-for-size syn-
drome, and also plays a role in hepatic repair after ischemia/reperfusion injury. Serotonin 
accumulates in thrombocytes and is released in areas of tissue injury stimulating mitogenesis 
[3]. All the mechanisms promoting liver regeneration and involving platelets are not yet very 
well understood but they certainly play an important role through the release of various medi-
ators like serotonin, hepatocyte growth factor, insulin growth factor, and vascular endothelial 
growth factor. The last one supports liver regeneration by stimulating neoangiogenesis [22].
3. Treating thrombocytopenia
Blood loss is a major concern during liver transplantation due to the precarious hemostatic 
condition of these patients combined to a surgical procedure at high risk for bleeding. Since the 
beginnings of LT, surgical techniques and anesthetic patient management have improved and 
the blood loss and transfusion needs have decreased. Despite life-saving benefits, transfusion 
has also related complications and platelet transfusion has been identified as an independent 
risk factor for postoperative complications. Risks related to platelet concentrate administra-
tion are allergic reactions, alloimmunization, bacterial sepsis, and transfusion-related acute 
lung injury (TRALI), and nowadays to a lesser extent viral transmission [23]. Therapeutic 
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rather than prophylactic administration of platelets concentrate is recommended with a pos-
sible threshold of 50,000/mm3 during surgery associated with diffuse bleeding [24].
In a study analyzing possible complications related to platelet administration during LT, 
Pereboom [25] has shown that patients who received platelet concentrates had lower patient 
and graft survival than patients who had only blood loss or low level of thrombocytes but 
were not transfused with platelets. Their main complication was related to platelet transfu-
sion and at the same time the specific cause of death was TRALI. TRALI is more frequently 
associated with plasma-rich blood products such as platelet concentrates and fresh frozen 
plasma and this might be related to the growth of inflammatory mediators in the stored plate-
lets. It has been shown that cytokine levels are 1000-fold greater in stored platelets when com-
pared to healthy volunteers and this might be related to the fact that platelets need to be kept 
at room temperature that also makes them prone to bacterial contamination. One could argue 
that transfusion needs are related to sicker patients but the author has shown that survival 
rates for those patients with severe blood loss and a low platelet count are similar to reference 
population if they were not transfused with platelet concentrates [25].
Despite the general consensus that platelet transfusions are related to worse outcome, there 
is a type of LT, the living-related LT where recipients might benefit from exogenous throm-
bocytes. Kim et al. on a series of 227 living-related LT conducted a study to define the effects 
of platelet transfusion on the liver regeneration and reached the conclusion that it has a ben-
eficial effect [26].
The use of blood products and fibrinogen concentrate following a thrombelastometry-guided 
protocol (TEG/ROTEM) has led to a decrease in overall transfusion requirements, platelet 
concentrates as well, by offering a picture of the complete coagulation process with informa-
tion on the dynamics of clot formation [27, 28].
Eltrombopag is an oral thrombopoietin-receptor agonist still looking for its place in the treat-
ment of thrombocytopenia in chronic liver disease. It has got an indication for patients with 
chronic HCV infection for the initiation or maintenance of interferon therapy. Afdhal et al. 
published in the name of the ELEVATE study group a paper showing that eltrombopag 
reduced the need for platelet transfusion in liver disease patients undergoing invasive pro-
cedures [29].
4. Conclusion
In conclusion, thrombocytopenia is a common figure of chronic liver disease and liver trans-
plant with multifactorial etiologies. Platelet count exclusively is not a good marker to antici-
pate risk for bleeding in cirrhotic patients because compensatory mechanisms increasing 
production of von Willebrand factor will interfere. Splenectomy is not indicated anymore as 
a therapeutic measure for regulating thrombocytopenia in the pretransplant period. It still 
may have some indications if done concomitantly with the transplant procedure especially in 
living-related LT or when small-for-size complication is anticipated.
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Thrombocytopenia will be aggravated during the surgical procedure due to bleeding and 
entrapment in the graft secondary to reperfusion. The decrease in platelet number will con-
tinue in the initial postoperative phase but a spontaneous resolution will take place if no 
complication.
Administration of platelets is not indicated if there is no bleeding or immediate bleeding 
risk. New emerging therapies like thrombopoietin-receptor agonist will furthermore limit the 
administration of blood products.
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